Gyre Therapeutics, Inc. (GYRE) Dividend History
Income profile from 2015 to 2024 with payout safety and yield-on-cost trend
3-Second Income Check
Safety
Payout ratio data not available yet.
Consistency
1 straight years of dividend increases.
Income Trend
Yield on cost trend needs more history.
Dividend Scorecard
Yield & Income
Payout Safety
Growth
Total Returns
Uses precomputed total return metrics from screening data (not lot-by-lot dividend reinvestment transactions). GYRE's recent 5Y regime has been stronger than its full 10Y period, so 5Y can appear higher than 10Y.
Income Growth Story
Dividend per share and yield on cost over time (3 years of payments)
Dividend Safety Story
EPS is the container — dividend is what's drawn out
Dividend Analysis
Payout Safety
Gyre Therapeutics, Inc. has limited earnings payout data (Unknown).
Piotroski F-Score: 4/9 — moderate financial health.
Growth Track Record
GYRE has raised its dividend for 1 consecutive year.
Total Shareholder Returns
Beyond cash dividends, GYRE returns capital through share repurchases. The combined picture: 0.0% total shareholder yield.
Income Trend & Total Return
The 5-year total return is -64.4%, with dividends contributing 26.8% of that performance.
DRIP Growth
A $10,000 investment made 10 years ago with dividends reinvested would have grown to approximately $736 today.
Recent Dividend Payments
Last 3 payments · Annual
| Ex-Date | Amount | Change | Yield % | Payment Date |
|---|---|---|---|---|
| Jan 13, 2023Latest | $3.6000 | ↓ -83.2% | 642.31% | — |
| Sep 21, 2022 | $21.4500 | ↓ -97.6% | 286.00% | — |
| Aug 20, 2015 | $896.1750 | — | 59.27% | — |
Dividend Peer Comparison
Peer group: Immunology and Inflammation Therapies
Annual Dividend History
21 years of dividend data
| Year | DPS | YoY | Pmts | EPS | Payout | Coverage | YOC |
|---|---|---|---|---|---|---|---|
| 2024 | $0.00 | -100.0% | 0 | $0.05 | — | — | — |
| 2023 | $3.60 | -83.2% | 1 | $-1.41 | — | — | 3.7% |
| 2022 | $21.45 | — | 1 | $0.03 | 71500.0% | 0.00x | 22.0% |
| 2021 | $0.00 | — | 0 | $-2.87 | — | — | — |
| 2020 | $0.00 | — | 0 | $-2.93 | — | — | — |
| 2019 | $0.00 | — | 0 | $-4.41 | — | — | — |
| 2018 | $0.00 | — | 0 | $-2.68 | — | — | — |
| 2017 | $0.00 | — | 0 | $-6.30 | — | — | — |
| 2016 | $0.00 | -100.0% | 0 | $-21.76 | — | — | — |
| 2015 | $896.17 | — | 1 | $-49.99 | — | — | 919.2% |
See GYRE's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs GYRE Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare GYRE vs AGIO
See how GYRE stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
How much dividend does GYRE pay per share?
Gyre Therapeutics, Inc. (GYRE) pays a trailing 12-month dividend of N/A per share, with a current dividend yield of N/A. Payments are made Annual.
When is GYRE's next ex-dividend date?
GYRE's most recent ex-dividend date is N/A. You must own shares before the ex-dividend date to receive the next payment. GYRE typically pays dividends Annual.
Is GYRE's dividend safe?
GYRE's dividend safety is rated "Unknown" based on an earnings payout ratio of N/A and FCF payout ratio of N/A. The 1-year growth streak provides moderate confidence.
How many years has GYRE increased its dividend?
GYRE has 1 consecutive years of dividend growth. The 5-year dividend CAGR is N/A.
How often does GYRE pay dividends?
Gyre Therapeutics, Inc. pays dividends Annual. The trailing 12-month total is N/A per share. Dividend data on this page covers 9+ years from 2015 to 2024.
How much would $10,000 invested in GYRE grow with dividend reinvestment?
With dividends reinvested (DRIP), $10,000 invested in GYRE five years ago would be worth approximately $3,562 today. This includes both price appreciation and compounded dividend reinvestment. Use the DRIP calculator above for other time periods.
What is GYRE's yield on cost for long-term holders?
GYRE's yield on cost — the current dividend divided by the original purchase price — is N/A for a 5-year holding period. This means long-term holders earn a higher effective yield than today's N/A market yield, thanks to the lower original cost basis.